The S&P 500 heads for a fifth day of declines, but drug stocks are a bright spot

Markets are broadly lower on Thursday, with the S&P 500 set for its fifth consecutive loss, erasing August's gains, primarily due to weakness in the 'Magnificent Seven' cohort. Conversely, the healthcare sector is outperforming, buoyed by pharmaceutical stocks like Eli Lilly and Bristol Myers Squibb, following news of a more manageable 15% US-EU tariff rate on branded pharma imports, significantly lower than previously threatened. Investors are also anticipating Fed Chair Jerome Powell's market-moving speech at Jackson Hole later today, alongside several key earnings reports.

Analysis

The broader market is experiencing a distinct risk-off sentiment, with the S&P 500 poised for its fifth consecutive daily loss, which has erased all of its gains for August. This downturn is largely attributable to weakness in the 'Magnificent Seven' cohort, causing the market-cap weighted S&P 500 to underperform the equal-weight RSP ETF and signaling a rotation out of high-multiple, momentum-driven stocks. In contrast, the healthcare sector is demonstrating notable resilience and is one of the few areas of strength. This outperformance is being driven by pharmaceutical stocks, which are rallying on news that a new US-EU trade framework will impose a 15% tariff on imported drugs—a significantly more manageable rate than the triple-digit tariffs previously feared, thereby reducing a major overhang of uncertainty. This development has provided a direct lift to shares of Bristol Myers Squibb and Eli Lilly. For Eli Lilly, this contributes to a rebound from a recent 14% plunge, with the stock now down less than 5% from its price before the sell-off. Investor focus is now shifting to key upcoming events, including retail earnings from Ross Stores and BJ's Wholesale, and most critically, Fed Chair Jerome Powell's speech at the Jackson Hole symposium, which is widely expected to be a market-moving event.

Key Decisions for Investors

• Investors should brace for continued market volatility ahead of the Jackson Hole symposium, as Fed Chair Powell's commentary on monetary policy will be a critical near-term catalyst.
• The healthcare sector, particularly pharmaceutical firms like Bristol Myers Squibb and Eli Lilly, is showing defensive characteristics and a positive tailwind from the reduced tariff uncertainty, making it a potential area for relative strength positioning.
• The ongoing rotation out of mega-cap tech suggests investors should re-evaluate exposure to the 'Magnificent Seven' and consider if equal-weight index strategies offer better diversification in the current environment.
• Monitor upcoming earnings from Ross Stores and BJ's Wholesale for confirmation of the consumer strength indicated by TJX's recent report, which could provide valuable insights into the health of the retail sector.